A Phase 3 interventional study of Neridronic acid in Complex Regional Pain Syndrome, sponsored by Grünenthal GmbH. Completed at 46 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-21.
Sponsored by Grünenthal GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Complex Regional Pain Syndromes with a site in United States — 20 open to participants now, 22 under way, 2 of them phase 3. Complex Regional Pain Syndromes · United States.
Among the 88 studies in Complex Regional Pain Syndromes with a site in United States, this one has the largest enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2016, is one of 12 in phase 3, and was the 42nd registered.
206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.
Browse Complex Regional Pain Syndromes studies →20 of the 88 studies in Complex Regional Pain Syndromes with a site in United States are open now. Recruiting first, the newest first:
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
Scripps Health · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Complex Regional Pain Syndromes studies recruiting now, 17 (44%) set no upper age limit and 16 (41%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 4
First in 2000; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 580 is above the median of 40 across 152 interventional studies indexed under Complex Regional Pain Syndromes.
Median enrollment 30 across the 67 interventional studies, 60 across the 21 observational. Of the 56 that completed or were terminated, 29 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 88 have an industry lead sponsor. The 10 most frequent:
Grünenthal GmbH is the lead sponsor of 69 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
Grünenthal GmbH has 3 studies filed under Complex Regional Pain Syndromes — fewer than ten, so there is no comparison to draw.
8 of the studies in Complex Regional Pain Syndromes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06798493Hospital for Special Surgery, New YorkCSS-SR Validation Study | 2026-12-29 |
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
| NCT05477004Theresa LiiObservational Study of Ketamine Infusions for the Treatment of Chronic Pain | 2026-12-31 |
| NCT05777889Hospital for Special Surgery, New YorkInfrared Images for Spinal Cord Stimulation in Complex Regional Pain Syndrome Patients | 2027-02 |
| NCT05814497Children's Hospital Medical Center, CincinnatiSupraspinal Processing of Sensory Aspects of Pain | 2027-06-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 88 studies in Complex Regional Pain Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this trial was to investigate the safety of intravenous neridronic acid in patients with complex regional pain syndrome (CRPS).
The trial was divided into 3 periods: a 60-day enrollment period, a treatment period consisting of 4 infusions over 10 days, and a follow-up period of approximately 50 weeks (with visits at Week 2, Week 6, Week 12, Week 26, Week 39, and Week 52).
At the Enrollment Visit the trial objectives, procedures, and risks were explained to the participants and the informed consent form was signed. Medical history was obtained, a physical examination was conducted, and other safety assessments were performed. Signs and symptoms of CRPS were assessed to confirm the diagnosis of CRPS according to the Budapest clinical criteria. Participants were trained to report their pain. Calcium and vitamin D supplementation were initiated to ensure sufficient vitamin D levels prior to treatment.
Participants meeting all eligibility criteria received infusions of investigational medicinal product (IMP) during visits on Day 1, Day 4, Day 7, and Day 10. Flexibility of ±1 day was allowed for Day 4, Day 7, and Day 10 whilst ensuring a minimum period of 48 hours between infusions. During the treatment period and follow-up period, pain intensity ratings were captured at the site visits in a patient reported-outcome system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neridronic acid 100 mg administered on Day 1, Day 4, Day 7, and Day 10, resulting in a total dose of neridronic acid 400 mg.
Drug: Neridronic acid
Neridronic acid administered as intravenous infusion.
Number of Participants With Occurrence of Any Treatment Emergent Adverse Event (TEAE)
The primary endpoint of this trial was a binary endpoint assessing whether or not a participant experienced any TEAE.
Time frame: Day 1 to Week 52
Number of Participants With Occurrence of Permanent Discontinuation From Treatment Due to an Adverse Event
The investigator could choose to permanently discontinue a participant from treatment if continued exposure of the participant to neridronic acid could have posed an undue risk to the participant.
Time frame: Day 1 to Day 10
Change From Baseline in the Current Pain Intensity Score
The current Complex Regional Pain Syndrome (CRPS)-related pain intensity score was captured at each visit using an 11-point numerical rating scale where 0 = "no pain" and 10 = "pain as bad as you can imagine", a higher score indicates more pain.
Time frame: Baseline to Week 12 and Week 26
Number of Participants With Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Current Pain Intensity Score
Participants with at least a 30 percent decrease in the current pain intensity score were considered to have responded to treatment.
Time frame: Baseline, at Week 12 and Week 26
Number of Participants With Response to Treatment, Defined as at Least 50% Decrease From Baseline in the Current Pain Intensity Score
Participants with at least a 50 percent decrease in the current pain intensity score were considered to have responded to treatment.
Time frame: Baseline, at Week 12 and Week 26
Patient Global Impression of Change (PGIC) at Week 12
The Patient Global Impression of Change (PGIC) is a self-reported measure of perceived change in overall condition since the start of the study. Participants selected one of seven responses ranging from "very much improved" to "very much worse". A response of "very much improved" or "much improved" is generally regarded as a clinically important improvement.
Time frame: at Week 12
Patient Global Impression of Change (PGIC) at Week 26
The Patient Global Impression of Change (PGIC) is a self-reported measure of perceived change in overall condition since the start of the study. Participants selected one of seven responses ranging from "very much improved" to "very much worse". A response of "very much improved" or "much improved" is generally regarded as a clinically important improvement.
Time frame: at Week 26
Change in the Pain Interference Score of the Brief Pain Inventory (BPI)
The Brief Pain Inventory (BPI) Interference Score is the mean value of 7 self-reported items in question 9 of the BPI Short Form Questionnaire. Participants rated their interference of pain with general activity, walking, work, sleep and other activities in the past 24 hours, with possible ratings from 0 (does not interfere) to 10 (completely interferes). The BPI interference Score ranges from 0 to 10, with higher values indicating greater pain interference of daily activities.
Time frame: Baseline to Week 12 and Week 26
The first participant was enrolled on 20 December 2016.
| Milestone | Neridronic Acid |
|---|---|
| Started | 318 |
| Completed | 247 |
| Not completed | 71 |
| Withdrew: Incl. criteria not met/exclusion met | 2 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Adverse event | 4 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 30 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Lost to follow-up | 26 |
| Withdrew: Other reasons | 5 |
| Withdrew: Missing | 1 |
The primary endpoint of this trial was a binary endpoint assessing whether or not a participant experienced any TEAE.
| Participants | Neridronic Acid |
|---|---|
| Participants with TEAE | 277 |
| Participants with serious TEAE | 27 |
| Participants with non-serious TEAE | 275 |
| Participants with unexpected TEAE | 267 |
| Participants with related TEAE | 190 |
| Participants with related serious TEAE | 3 |
| Participants with TEAE leading to IMP discont. | 12 |
| Participants with TEAE leading to trial discont. | 6 |
The investigator could choose to permanently discontinue a participant from treatment if continued exposure of the participant to neridronic acid could have posed an undue risk to the participant.
| Participants | Neridronic Acid |
|---|---|
| Number of Participants With Occurrence of Permanent Discontinuation From Treatment Due to an Adverse Event | 12 |
The current Complex Regional Pain Syndrome (CRPS)-related pain intensity score was captured at each visit using an 11-point numerical rating scale where 0 = "no pain" and 10 = "pain as bad as you can imagine", a higher score indicates more pain.
| units on a scale | Neridronic Acid |
|---|---|
| Baseline to Week 12 | -1.54 ± 2.27 |
| Baseline to Week 26 | -1.57 ± 2.45 |
Participants with at least a 30 percent decrease in the current pain intensity score were considered to have responded to treatment.
| Participants | Neridronic Acid |
|---|---|
| At least 30% pain reduction - Week 12 | 105 |
| At least 30% pain reduction - Week 26 | 110 |
Participants with at least a 50 percent decrease in the current pain intensity score were considered to have responded to treatment.
| Participants | Neridronic Acid |
|---|---|
| At least 50% pain reduction - Week 12 | 75 |
| At least 50% pain reduction - Week 26 | 74 |
The Patient Global Impression of Change (PGIC) is a self-reported measure of perceived change in overall condition since the start of the study. Participants selected one of seven responses ranging from "very much improved" to "very much worse". A response of "very much improved" or "much improved" is generally regarded as a clinically important improvement.
| Participants | Neridronic Acid |
|---|---|
| Very Much Improved | 31 |
| Much Improved | 71 |
| Minimally Improved | 98 |
| No Change | 45 |
| Minimally Worse | 23 |
| Much Worse | 12 |
| Very Much Worse | 3 |
| Missing | 3 |
The Patient Global Impression of Change (PGIC) is a self-reported measure of perceived change in overall condition since the start of the study. Participants selected one of seven responses ranging from "very much improved" to "very much worse". A response of "very much improved" or "much improved" is generally regarded as a clinically important improvement.
| Participants | Neridronic Acid |
|---|---|
| Very Much Improved | 38 |
| Much Improved | 58 |
| Minimally Improved | 84 |
| No Change | 52 |
| Minimally Worse | 25 |
| Much Worse | 10 |
| Very Much Worse | 2 |
| Missing | 4 |
The Brief Pain Inventory (BPI) Interference Score is the mean value of 7 self-reported items in question 9 of the BPI Short Form Questionnaire. Participants rated their interference of pain with general activity, walking, work, sleep and other activities in the past 24 hours, with possible ratings from 0 (does not interfere) to 10 (completely interferes). The BPI interference Score ranges from 0 to 10, with higher values indicating greater pain interference of daily activities.
| score on a scale | Neridronic Acid |
|---|---|
| Baseline to Week 12 | -2.2 ± 2.49 |
| Baseline to Week 26 | -2.1 ± 2.64 |
Collected over Day 1 to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Neridronic Acid | 1/316 (0.3%) | 27/316 (8.5%) | 275/316 (87%) |
| Event | Neridronic Acid |
|---|---|
| Chest painGeneral disorders | 2/316 |
| PneumoniaInfections and infestations | 2/316 |
| FallInjury, poisoning and procedural complications | 2/316 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/316 |
| SyncopeNervous system disorders | 2/316 |
| Suicide attemptPsychiatric disorders | 2/316 |
| Angina unstableCardiac disorders | 1/316 |
| Myocardial infarctionCardiac disorders | 1/316 |
| Stress cardiomyopathyCardiac disorders | 1/316 |
| Abdominal painGastrointestinal disorders | 1/316 |
| Event | Neridronic Acid |
|---|---|
| HeadacheNervous system disorders | 65/316 |
| MyalgiaMusculoskeletal and connective tissue disorders | 52/316 |
| NauseaGastrointestinal disorders | 34/316 |
| FatigueGeneral disorders | 32/316 |
| Condition aggravatedGeneral disorders | 30/316 |
| PainGeneral disorders | 28/316 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 27/316 |
| Back painMusculoskeletal and connective tissue disorders | 25/316 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 25/316 |
| PyrexiaGeneral disorders | 18/316 |
| Age, Categorical(Participants) | Neridronic Acid |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 290 |
| >=65 years | 26 |
| Age, Continuous(years) | Neridronic Acid |
|---|---|
| Mean | 47.4 (19 to 77) |
| Sex: Female, Male(Participants) | Neridronic Acid |
|---|---|
| Female | 237 |
| Male | 79 |
| Ethnicity (NIH/OMB)(Participants) | Neridronic Acid |
|---|---|
| Hispanic or Latino | 16 |
| Not Hispanic or Latino | 300 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Neridronic Acid |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 8 |
| White | 297 |
| More than one race | 3 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Neridronic Acid |
|---|---|
| United States | 308 |
| Germany | 8 |
| Body mass index (BMI)(kg/m^2) | Neridronic Acid |
|---|---|
| Mean | 28.3 ± 7.4 |
| Baseline current pain intensity 11-point NRS(units on a scale) | Neridronic Acid |
|---|---|
| Mean | 6.59 ± 1.58 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Information available on the Grünenthal Web Site
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Data sharing details ↗ · www.grunenthal.com
Ran from Dec 2016 to primary completion in Jan 2019, 24 months.
Results were first posted in Nov 2019, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Neridronic acid
Complex Regional Pain Syndromes →